<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014335</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 696844-CS4</org_study_id>
    <nct_id>NCT04014335</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy</brief_title>
  <official_title>An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of IONIS-FB-LRx, an
      antisense inhibitor of complement factor B messenger ribonucleic acid (CFB mRNA), and to
      evaluate the effect of IONIS-FB-LRx on plasma factor B (FB) levels and serum AH50, CH50
      activity in participants with primary immunoglobulin A (IgA) nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, single arm open-label clinical study in up to 10 participants that will
      consist of screening period (which may include a titration of maximum dose/maximally
      tolerated dose of angiotensin converting enzyme (ACE) and/or angiotensin II receptor blocker
      (ARB)), a 24-week treatment period and a 12-week post-treatment follow-up evaluation period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Reduction in 24-hour Urine Protein Excretion</measure>
    <time_frame>Baseline to Week 29 (If participant discontinues Study Drug prior to Week 25, Baseline and 4 weeks after the last dose of Study Drug will be measured)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Reduction in 24-hour Urine Protein Excretion</measure>
    <time_frame>Baseline to Week 29 (If participant discontinues Study Drug prior to Week 25, Baseline and 4 weeks after the last dose of Study Drug will be measured)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Reduction in Albuminuria (UACr Ratio)</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Reduction in Proteinuria (UPCr Ratio)</measure>
    <time_frame>Baseline to Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Plasma Factor B (FB)</measure>
    <time_frame>Up to Week 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Plasma AH50</measure>
    <time_frame>Up to Week 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Primary IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>IONIS-FB-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-FB-LRx</intervention_name>
    <description>Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Weeks 1, 3, 5, and every 4 weeks through Week 25.</description>
    <arm_group_label>IONIS-FB-LRx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or
             post-menopausal OR use a highly effective method of birth control

          -  Biopsy-proven primary immunoglobulin A (IgA) nephropathy

          -  Hematuria

          -  Proteinuria

        Exclusion Criteria

          -  Clinically significant abnormalities in medical history (e.g., dementia, stroke, acute
             coronary syndrome, thrombocytopenia, or major surgery within 6 months of Screening)

          -  Diagnosis of primary or secondary immunodeficiencies of B-lymphocyte function,
             splenectomy, or history of recurrent meningococcal disease

          -  Active infection 30 days prior to study

          -  Estimated glomerular filtration rate (eGFR) â‰¤ 40 milliliters per minute per 1.73
             square meters (mL/min/1.73m^2) using the Chronic Kidney Disease Epidemiology
             Collaboration (CKD-EPI)

          -  Presence of another renal disease including, but not limited to, diabetes and/or
             diabetic nephropathy, thin basement membrane disease, Alport's disease, IgA Nephritis
             (Henoch-Schonlein purpura), lupus nephritis, Minimal Change Disease, post-infectious
             glomerulonephritis or any other cause of proteinuria or secondary IgA nephropathy
             (including, but not limited to Celiac disease, Crohn's disease, human immunodeficiency
             virus (HIV), liver cirrhosis)

          -  History of renal transplant or another organ transplant

          -  Treatment with another investigational drug, biological agent, or device within 6
             months of screening investigational agent, whichever is longer

          -  Administration of immunosuppressive/immunomodulatory medication 12 months prior to
             study drug administration, except for short-term treatments.

          -  Other protocol-specified inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(02) 8738 3710</phone>
      <email>Michael.suranyi@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(04) 5756 7527</phone>
      <email>muhgeot.wong@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(03) 9342 8530</phone>
      <email>research@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>604-806-9460</phone>
      <email>kvela@providencehealth.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>416-480-6100 x 3247</phone>
      <email>anny.gonzalez@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <phone>416-480-6100 x 83705</phone>
      <email>tatjana.sukovic@sunnybrook.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+64 (0) 3 3729 477</phone>
      <email>research@ccst.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

